FI4419526T3 - Heterosyklisiä yhdisteitä käytettäväksi syövän hoidossa - Google Patents

Heterosyklisiä yhdisteitä käytettäväksi syövän hoidossa Download PDF

Info

Publication number
FI4419526T3
FI4419526T3 FIEP22797829.3T FI22797829T FI4419526T3 FI 4419526 T3 FI4419526 T3 FI 4419526T3 FI 22797829 T FI22797829 T FI 22797829T FI 4419526 T3 FI4419526 T3 FI 4419526T3
Authority
FI
Finland
Prior art keywords
compound
formula
cancer
treatment
heterocyclic compounds
Prior art date
Application number
FIEP22797829.3T
Other languages
English (en)
Finnish (fi)
Inventor
Owen Davis
Robert Heald
Martin Stockley
Harry Finch
Sam Mann
Original Assignee
Artios Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artios Pharma Ltd filed Critical Artios Pharma Ltd
Application granted granted Critical
Publication of FI4419526T3 publication Critical patent/FI4419526T3/fi

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP22797829.3T 2021-10-21 2022-10-21 Heterosyklisiä yhdisteitä käytettäväksi syövän hoidossa FI4419526T3 (fi)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2115156.8A GB202115156D0 (en) 2021-10-21 2021-10-21 Novel compounds
PCT/GB2022/052690 WO2023067356A1 (en) 2021-10-21 2022-10-21 Heterocyclic compounds for use in the treatment of cancer

Publications (1)

Publication Number Publication Date
FI4419526T3 true FI4419526T3 (fi) 2025-02-13

Family

ID=78805918

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP22797829.3T FI4419526T3 (fi) 2021-10-21 2022-10-21 Heterosyklisiä yhdisteitä käytettäväksi syövän hoidossa

Country Status (24)

Country Link
US (1) US20240425511A1 (https=)
EP (2) EP4419526B1 (https=)
JP (2) JP2024539132A (https=)
KR (1) KR20240099274A (https=)
CN (2) CN119053600A (https=)
AR (1) AR127431A1 (https=)
AU (1) AU2022374050A1 (https=)
CA (1) CA3233255A1 (https=)
DK (1) DK4419526T3 (https=)
ES (1) ES3008687T3 (https=)
FI (1) FI4419526T3 (https=)
GB (1) GB202115156D0 (https=)
HR (1) HRP20250334T1 (https=)
HU (1) HUE070568T2 (https=)
IL (1) IL311922A (https=)
LT (1) LT4419526T (https=)
MX (1) MX2024004874A (https=)
PL (1) PL4419526T3 (https=)
PT (1) PT4419526T (https=)
RS (1) RS66620B1 (https=)
SI (1) SI4419526T1 (https=)
SM (1) SMT202500123T1 (https=)
TW (1) TW202334150A (https=)
WO (2) WO2023067355A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025077896A1 (zh) * 2023-10-12 2025-04-17 上海湃隆生物科技有限公司 一种DNA聚合酶theta抑制剂及其应用
CN118084767B (zh) * 2024-04-02 2025-06-17 康龙化成手性医药技术(宁波)有限公司 一种外型-6-氟甲基-3-氮杂双环[3,1,0]己烷盐酸盐及其衍生物的合成方法
WO2025214463A1 (zh) * 2024-04-13 2025-10-16 正大天晴药业集团股份有限公司 含有三并环结构的化合物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017062754A1 (en) 2015-10-07 2017-04-13 New York University Compositions and methods for enhancing crispr activity by polq inhibition
US12358886B2 (en) * 2019-08-09 2025-07-15 Artios Pharma Limited Heterocyclic compounds for use in the treatment of cancer

Also Published As

Publication number Publication date
PL4419526T3 (pl) 2025-04-22
SMT202500123T1 (it) 2025-05-12
LT4419526T (lt) 2025-03-25
EP4419527A1 (en) 2024-08-28
HRP20250334T1 (hr) 2025-06-06
US20240425511A1 (en) 2024-12-26
JP2024542949A (ja) 2024-11-19
DK4419526T3 (da) 2025-02-17
EP4419526A1 (en) 2024-08-28
ES3008687T3 (en) 2025-03-24
CA3233255A1 (en) 2023-04-27
PT4419526T (pt) 2025-02-03
RS66620B1 (sr) 2025-04-30
WO2023067355A1 (en) 2023-04-27
EP4419526B1 (en) 2024-12-25
CN119053600A (zh) 2024-11-29
IL311922A (en) 2024-06-01
JP2024539132A (ja) 2024-10-28
CN118234728A (zh) 2024-06-21
KR20240099274A (ko) 2024-06-28
GB202115156D0 (en) 2021-12-08
WO2023067356A1 (en) 2023-04-27
SI4419526T1 (sl) 2025-05-30
AU2022374050A1 (en) 2024-05-02
AR127431A1 (es) 2024-01-24
HUE070568T2 (hu) 2025-06-28
TW202334150A (zh) 2023-09-01
MX2024004874A (es) 2024-05-06

Similar Documents

Publication Publication Date Title
FI4419526T3 (fi) Heterosyklisiä yhdisteitä käytettäväksi syövän hoidossa
RU2591191C2 (ru) Трициклические пирроло производные, способ их получения и их применение в качестве ингибиторов киназы
ZA202001390B (en) Crystalline forms
GEP20257767B (en) Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors
NZ766835A (en) Pharmaceutical compounds
AR119210A1 (es) DERIVADOS DE PIRROLO[1,2-c]IMIDAZOL COMO INHIBIDORES DE EGFR
PE20151249A1 (es) Derivados de pirazolopirimidina como inhibidores de jak quinasas
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
GEP20156417B (en) Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases
TW200621762A (en) Novel compounds
ATE370138T1 (de) Neue imidazopyridine und ihre verwendung
NO20092737L (no) Substituerte pyrazolo-kinazolinderivater, fremgangsmate for deres fremstilling og deres anvendelse som kinase-inhibitorer
MX2010004819A (es) Derivados de [1h-pirazolo[3,4-b]piridin-4-il]-fenilo o piridin-2-ilo como proteina cinasa c-theta.
JO2503B1 (en) Benzathiazole derivatives
JP2012532131A5 (https=)
MXPA05001585A (es) Nuevo uso de derivados de benzotiazol.
HRP20090459T1 (hr) Aminofenil derivati kao novi inhibitori histonskih deacetilaza
NZ700583A (en) Novel 7-deazapurine nucleosides for therapeutic uses
JP2018501315A5 (https=)
NZ590954A (en) Compounds as kinase inhibitors
PE20090944A1 (es) PIRIMIDINAS BICICLICAS FUSIONADAS COMO INHIBIDORES DE LA VIA Pi3K/AKT
JP2024542949A5 (https=)
NZ598144A (en) Kinase inhibitors, prodrug forms thereof and their use in therapy
NZ593797A (en) Derivatives of 2-pyridin-2-yl-pyrazol-3(2h)-one, preparation and therapeutic use thereof
JP2004525972A5 (https=)